SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cohen J.I., Straus S.E., Arvin A.M. (2007) Varicella–Zoster Virus Replication, Pathogenesis, and Management, 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins.
  • 2
    Takahashi M., Asano Y., Kamiya H., Baba K., Ozaki T., Otsuka T., Yamanishi K. (2008) Development of varicella vaccine. J Infect Dis 197 (Suppl 2): S414.
  • 3
    Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T. (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2: 128890.
  • 4
    Chaves S.S., Haber P., Walton K., Wise R.P., Izurieta H.S., Schmid D.S., Seward, J.F. (2008) Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995- 2005. J Infect Dis 197 (Suppl 2): S1707.
  • 5
    Galea S.A., Sweet A., Beninger P., Steinberg S.P., Larussa P.S., Gershon A.A., Sharrar R.G. (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197 (Suppl 2): S1659.
  • 6
    Gershon A.A. (2007) Varicella–zoster vaccine. In Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press. Chapter 70: 12621273.
  • 7
    Takahashi M. (2004) Effectiveness of live varicella vaccine. Expert Opin Biol Ther 4: 199216.
  • 8
    Lowe R.S., Keller P.M., Keech B.J., Davison A.J., Whang Y., Morgan A.J., Kieff E. Ellis R.W. (1987) Varicella–zoster virus as a live vector for the expression of foreign genes. Proc Natl Acad Sci USA 84: 3896900.
  • 9
    Shiraki K., Hayakawa Y., Mori H., Namazue J., Takamizawa A., Yoshida I., Yamanishi K., Takahashi M. (1991) Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen. J Gen Virol 72(Pt 6): 13939.
  • 10
    Shiraki K., Sato H., Yoshida Y., Yamamura J.I., Tsurita M., Kurokawa M., Kageyama S. (2001) Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen. J Med Virol 64: 8995.
  • 11
    Heineman T.C., Pesnicak L., Ali M.A., Krogmann T., Krudwig N., Cohen J.I. (2004) Varicella–zoster virus expressing HSV-2 glycoproteins B and D induces protection against HSV-2 challenge. Vaccine 22: 255865.
  • 12
    Adler H., Messerle M., Koszinowski U.H. (2001) Virus reconstituted from infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences. J Virol 75: 56926.
  • 13
    Nagaike K., Mori Y., Gomi Y., Yoshii H., Takahashi M., Wagner M., Koszinowski U., Yamanishi K. (2004) Cloning of the varicella–zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli. Vaccine 22: 406974.
  • 14
    Yoshii H., Somboonthum P., Takahashi M., Yamanishi K., Mori Y. (2007) Cloning of full length genome of varicella–zoster virus vaccine strain into a bacterial artificial chromosome and reconstitution of infectious virus. Vaccine 25: 500612.
  • 15
    Carbone K.M., Rubin S. (2007) Mumps Virus, 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins.
  • 16
    Wellington K., Goa K.L. (2003) Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Drugs 63: 210726.
  • 17
    Midulla M., Chiavelli, S. (1984) Vaccination against epidemic parotitis. Pediatr Med Chir 6: 2530.
  • 18
    World Health Organization (2001) Mumps virus vaccines. Wkly Epidemiol Rec 76: 34655.
  • 19
    Nalin D.R. (1989) Mumps vaccine complications: which strain? Lancet 2: 1396.
  • 20
    Miller E., Goldacre M., Pugh S., Colville A., Farrington P., Flower A., Nash J., Macfarlane L., Tettmar R. (1993) Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 341: 97982.
  • 21
    Kimura M., Kuno-Sakai H., Yamazaki S., Yamada A., Hishiyama M., Kamiya H., Ueda K., Murase T., Hirayama M., Oya A., Nozaki S., Murata R. (1996) Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn 38: 20511.
  • 22
    Jonville-Bera A.P., Autret E., Galy-Eyraud C., Hessel L. (1996) Aseptic meningitis following mumps vaccine. A retrospective survey by the French Regional Pharmacovigilance centres and by Pasteur-Merieux Serums and Vaccines. Pharmacoepidemiol Drug Saf 5: 337.
  • 23
    Cizman M., Mozetic M., Radescek-Rakar R., Pleterski-Rigler D., Susec-Michieli M. (1989) Aseptic meningitis after vaccination against measles and mumps. Pediatr Infect Dis J 8: 3028.
  • 24
    Orvell C. (1978) Immunological properties of purified mumps virus glycoproteins. J Gen Virol 41: 51726.
  • 25
    Orvell C. (1984) The reactions of monoclonal antibodies with structural proteins of mumps virus. J Immunol 132: 26229.
  • 26
    Wolinsky J.S., Waxham M.N., Server A.C. (1985) Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J Virol 53: 72734.
  • 27
    Somboonthum P., Yoshii H., Okamoto S., Koike M., Gomi Y., Uchiyama Y., Takahashi M., Yamanishi K., Mori Y. (2007) Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine. Vaccine 25: 874155.
  • 28
    Love A., Rydbeck R., Utter G., Orvell C., Kristensson K., Norrby E. (1986) Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis. J Virol 58: 2202.
  • 29
    Houard S., Varsanyi T.M., Milican F., Norrby E., Bollen A. (1995) Protection of hamsters against experimental mumps virus (MuV) infection by antibodies raised against the MuV surface glycoproteins expressed from recombinant vaccinia virus vectors. J Gen Virol 76(Pt 2): 4213.
  • 30
    Somboonthum P., Koshizuka T., Okamoto S., Matsuura M., Gomi Y., Takahashi M., Yamanishi K., Mori Y. (2010) Rapid and efficient introduction of a foreign gene into bacterial artificial chromosome-cloned varicella vaccine by Tn7-mediated site-specific transposition. Virology 402: 21521.
  • 31
    Niwa H., Yamamura K., Miyazaki J. (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108: 1939.
  • 32
    Tanaka M., Kagawa H., Yamanashi Y., Sata T., Kawaguchi Y. (2003) Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. J Virol 77: 138291.
  • 33
    Tischer B.K., Von Einem J., Kaufer B., Osterrieder N. (2006) Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40: 1917.
  • 34
    Koshizuka T., Ota M., Yamanishi K., Mori Y. (2010) Characterization of varicella–zoster virus-encoded ORF0 gene—comparison of parental and vaccine strains. Virology 405: 2808.
  • 35
    Tischer B.K., Smith G.A., Osterrieder N. (2010) En passant mutagenesis: a two step markerless red recombination system. Methods Mol Biol 634: 42130.
  • 36
    Tanabayashi K., Takeuchi K., Hishiyama M., Yamada A. (1994) Effect on fusion induction of point mutations introduced into the F protein of mumps virus. Virology 204: 8513.
  • 37
    Tanabayashi K., Takeuchi K., Okazaki K., Hishiyama M., Yamada A. (1993) Identification of an amino acid that defines the fusogenicity of mumps virus. J Virol 67: 292831.
  • 38
    Tsurudome M., Yamada A., Hishiyama M., Ito Y. (1986) Monoclonal antibodies against the glycoproteins of mumps virus: fusion inhibition by anti-HN monoclonal antibody. J Gen Virol 67(Pt 10): 225965.
  • 39
    Jensik S.C., Silver, S. (1976) Polypeptides of mumps virus. J Virol 17: 36373.
  • 40
    Server A.C., Merz D.C., Waxham M.N., Wolinsky J.S. (1982) Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein. Infect Immun 35: 17986.
  • 41
    Morrison T.G. (2003) Structure and function of a paramyxovirus fusion protein. Biochim Biophys Acta 1614: 7384.
  • 42
    Takimoto T., Taylor G.L., Connaris H.C., Crennell S.J., Portner, A. (2002) Role of the hemagglutinin-neuraminidase protein in the mechanism of paramyxovirus-cell membrane fusion. J Virol 76: 1302833.
  • 43
    Tanabayashi K., Takeuchi K., Okazaki K., Hishiyama M., Yamada A. (1992) Expression of mumps virus glycoproteins in mammalian cells from cloned cDNAs: both F and HN proteins are required for cell fusion. Virology 187: 8014.
  • 44
    Lalioti M., Heath J. (2001) A new method for generating point mutations in bacterial artificial chromosomes by homologous recombination in Escherichia coli. Nucleic Acids Res 29: E14.